Wednesday, 16 Oct 2019

You are here

Statin Side Effects Are For Real

The GAUSS-3 trial, recently published in JAMA, examined cholesterol-lowering interventions in patients with a high LDL (>120 mg/dl) and a history of statin intolerance to 2 or more statins. 

In the first part of the trial, 491 patients were blindly randomized to either placebo or atorvastatin. In this 24 week crossover trial, 42.6 percent of the patients reported muscle-related side effects during statin use, but not with placebo. However, 26.5 percent experienced muscle pain while taking the placebo – something not attributable to statin intake. 

Despite their efficacy, a significant number of patients report muscle weakness or pain while on statin therapy.  These results are important, since most large randomized trials of statins fail to show the high rates of myalgic symptoms noted in open-label or observational reports. 

In the second phase of this trial, those with confirmed statin intolerance were randomized to two "non-statin" therapies: the PCSK9 inhibitor evolocumab (Repatha) or ezetimibe (Zetia; decreases cholesterol absorption in the small intestine). Evolucumab is a new injectable monoclonal antibody that inhibits proprotein convertase subtilisin/kexin 9 (PCSK9) and has been touted for those intolerant of statins.

After six months, evolocumab was superior to ezetimibe (50% vs 17%) in lowering cholesterol levels. Muscle symptoms were reported in 28.8% of ezetimibe-treated patients and 20.7% of evolocumab-treated patients. Discontinueations for muscle symptoms was higher in ezetimibe-treated patients (6.8%) than evolocumab-treated patients (0.7%).

The researchers concluded that those who suffer muscle-related symptoms while on statin therapy may benefit from evolocumab as an alternative treatment to continue lowering their LDL or “bad” cholesterol.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Hydroxychloroquine Blood Levels May Predict Future Retinopathy

A study of 527 patients receiving daily hydroxychloroquine (HCQ) concluded that hydroxychloroquine blood levels may predict future HCQ retinopathy.

This study assessed whether lower HCQ dosing, as recommended by the 2016 American Academy of Ophthalmology (AAO) guidelines (less than 5 mg/kg), would favorably affect retinopathy outcomes.

Arthritis Foundation Releases First CBD Guidance for Adults With Arthritis

As the leading organization for people with arthritis, the Arthritis Foundation has just released the first CBD guidance for adults with arthritis. CBD, or cannabidiol, a plant-based compound, has become popular among people with arthritis seeking to ease chronic joint pain.

Persistent Inflammatory Arthritis After Immune Checkpoint Inhibitors

Braaten and colleagues from Johns Hopkins School of Medicine have reported their experience with chronic inflammatory arthritis induced by immune checkpoint inhibitor therapies, showing that in some, inflammatory arthritis persists after the immunotherapy has been discontinued.

Checkpoint Inhibitors: Who Gets Myocarditis?

The usual risk factors for myocarditis may not apply to who gets it while on immune checkpoint inhibiting cancer drugs, an FDA adverse event database suggested.

NSAIDs Mediate Cardiovascular Risk in OA

NSAIDs have been linked to an increased risk of cardiovascular disease, but does this also hold for osteoarthritis (OA) patients.